Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Accumulated Expenses (2017 - 2026)

Arcus Biosciences has reported Other Accumulated Expenses over the past 9 years, most recently at $154.0 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 25.2% year-over-year to $154.0 million; the TTM value through Dec 2025 reached $154.0 million, up 25.2%, while the annual FY2025 figure was $154.0 million, 25.2% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $154.0 million at Arcus Biosciences, up from $141.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $154.0 million in Q4 2025 and troughed at $341000.0 in Q1 2021.
  • A 5-year average of $65.8 million and a median of $67.5 million in 2024 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 68.17% in 2021 and later soared 9115.53% in 2022.
  • Year by year, Other Accumulated Expenses stood at $54.0 million in 2021, then skyrocketed by 40.74% to $76.0 million in 2022, then changed by 0.0% to $76.0 million in 2023, then skyrocketed by 61.84% to $123.0 million in 2024, then rose by 25.2% to $154.0 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for RCUS at $154.0 million in Q4 2025, $141.0 million in Q3 2025, and $110.0 million in Q2 2025.